[Clinical evaluation of female pelvic tumors : Application fields of integrated PET/MRI].
Integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning has recently become established in clinical imaging. Various studies have demonstrated the great potential of this new hybrid imaging procedure for applications in the field of oncology and the diagnostics of inflammatory processes. With initial studies demonstrating the feasibility and high diagnostic potential of PET/MRI comparable to PET-computed tomography (CT), the focus of future studies should be on the identification of application fields with a potential diagnostic benefit of PET/MRI over other established diagnostic tools. Both MRI and PET/CT are widely used in the diagnostic algorithms for malignancies of the female pelvis. A simultaneous acquisition of PET and MRI data within a single examination provides complementary information which can be used for a more comprehensive evaluation of the primary tumor as well as for whole body staging. Therefore, the aim of this article is to outline potential clinical applications of integrated PET/MRI for the diagnostic work-up of primary or recurrent gynecological neoplasms of the female pelvis.
Institut für diagnostische und interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland. Johannes.grueneisen@uk-essen.de.
J
J
Grueneisen
Institut für diagnostische und interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
L
L
Umutlu
D014408:Biomarkers, Tumor / Q000378:metabolism; D003937:Diagnosis, Differential; D005260:Female; D005833:Genital Neoplasms, Female / Q000000981:diagnostic imaging*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D057054:Molecular Imaging / Q000379:methods*; D064847:Multimodal Imaging / Q000379:methods*; D010386:Pelvic Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014057:Tomography, X-Ray Computed / Q000379:methods
D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals
Female pelvic malignancies; Multiparametric imaging; Positron emission tomography/magnetic resonance imaging (PET/MRI); Therapy response assessment; Tumor staging